Evaluation of Bone Metabolism Biomarkers in Paget's Disease of Bone

Evaluation of Bone Metabolism Biomarkers in Paget's Disease of Bone

To evaluate serum levels of bone metabolism biomarkers in patients with Paget's disease of bone (PDB). Serum levels of osteopontin, sclerostin, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin, Dickkopf-related protein 1 (DKK-1), and soluble frizzled-related protein...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) Vol. 11; no. 5; p. e4791
Main Authors: Werner de Castro, Glaucio R, Buss, Ziliani Da Silva, Rosa, Julia Salvan, Facchin, Bruno M, Fröde, Tania S
Format: Journal Article
Language:English
Published: United States Cureus Inc 31-05-2019
Cureus
Subjects:
Acids
Age groups
Arthritis
Biomarkers
Clinical medicine
Cytokines
Enzymes
Internal Medicine
Metabolism
Older people
Patients
Phosphatase
Rheumatology
Tumors
Variance analysis
X-rays
paget's disease of bone
rankl
sfrp-1
osteopontin
dkk-1
osteoprotegerin
sclerostin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate serum levels of bone metabolism biomarkers in patients with Paget's disease of bone (PDB). Serum levels of osteopontin, sclerostin, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin, Dickkopf-related protein 1 (DKK-1), and soluble frizzled-related protein 1 (sFRP-1) were measured in 57 patients with Paget's disease of bone and 24 controls with primary osteoarthritis. Subgroup analysis was employed to identify any differences in bone metabolism biomarker levels according to disease activity or current treatment. Patients with PDB presented higher levels of osteopontin and RANKL. When compared with patients with inactive disease, patients with active disease presented higher levels of bone-specific alkaline phosphatase (BAP) and osteopontin. There was a significant correlation between serum levels of BAP and osteopontin. There was no significant correlation between levels of BAP and other bone metabolism biomarkers. Current disease extension on bone scintigraphy had a significant correlation with serum levels of osteopontin and BAP. There was no significant correlation between current disease extension and other bone metabolism biomarkers. Serum levels of osteopontin and RANKL were correlated to serum levels of BAP and disease extension. Patients with PDB presented higher levels of osteopontin and RANKL. Osteopontin could be a useful biomarker for activity and extension of PDB.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.4791